Leica Biosystems has announced that it will acquire the anatomical pathology product manufacturer StatLab Medical Products (StatLab) from Linden Capital Partners and Audax Private Equity.
Leica Biosystems, a subsidiary of Danaher, announced the purchase on Tuesday, but did not disclose the financial terms of the acquisition.
The transaction is expected to close by the end of this year.
StatLab provides high-quality products that enhance efficiency and diagnostic quality throughout the histology workflow for anatomic pathology laboratories.
The addition of the company will expand Leica Biosystems' computational pathology platform with StatLab's workflow portfolio, which spans specimen collection through to slide staining, supporting laboratory standardisation for AI-driven cancer diagnostics.
"We are excited by the opportunity to combine StatLab's trusted portfolio with Leica Biosystems' global leadership in pathology, computational pathology and AI-enabled diagnostics," said Gustavo Perez Fernandez, Group Executive, Danaher's Diagnostics business and President, Leica Biosystems.
Together, we can solve some of the hardest problems in healthcare by helping laboratories achieve the consistency, standardisation and quality required to adopt AI-enabled cancer diagnostics at scale.
"We look forward to welcoming this talented team to Leica Biosystems. Every step we take to accelerate critical cancer diagnostics helps patients get on the path to treatment faster."
